This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sader, H. S.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sader, H. S.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2007, p. 1640-1643, Vol. 45, No. 5
0095-1137/07/$08.00+0     doi:10.1128/JCM.00143-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Reevaluation of Clinical and Laboratory Standards Institute Disk Diffusion Breakpoints for Tetracyclines for Testing Enterobacteriaceae{triangledown}

Helio S. Sader,1* Mary J. Ferraro,2 L. Barth Reller,3 Paul C. Schreckenberger,4 Jana M. Swenson,5 and Ronald N. Jones1

JMI Laboratories, North Liberty, Iowa,1 Massachusetts General Hospital, Boston, Massachusetts,2 Duke University, Durham, North Carolina,3 Loyola University Chicago, Chicago, Illinois,4 CDC, Atlanta, Georgia5

Received 19 January 2007/ Returned for modification 11 February 2007/ Accepted 2 March 2007

We reevaluated Enterobacteriaceae disk diffusion breakpoints for the tetracyclines published in the Clinical and Laboratory Standards Institute (CLSI) document M100-S16, which were (susceptible/resistant) ≥19 mm/≤14 mm for tetracycline, ≥16 mm/≤12 mm for doxycycline, and ≥19 mm/≤14 mm for minocycline. A collection of 504 recent clinical isolates of Enterobacteriaceae were tested against these tetracycline compounds by disk diffusion and broth microdilution methods according to CLSI guidelines. Regression line and scattergram plot analyses determined intermethod accuracy for current disk diffusion breakpoints and showed excellent r values of 0.91 to 0.95. However, error rates (minor/major [false-resistant]/very major [false-susceptible]) were 14.9/0.8/0.0% for tetracycline, 11.5/0.4/0.0% for doxycycline, and 30.6/0.7/0.0% for minocycline and only 4.4/0.0/0.0% for tetracycline, 5.6/0.0/0.2% for doxycycline, and 8.3/0.0/0.3% for minocycline when proposed breakpoints were modified to (susceptible/resistant) ≥15 mm/≤11 mm for tetracycline, ≥14 mm/≤10 mm for doxycycline, and ≥16 mm/≤12 mm for minocycline. Listed modifications were recently approved by the CLSI (M100-S17).

* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: helio-sader{at}jmilabs.com

{triangledown} Published ahead of print on 14 March 2007.

Journal of Clinical Microbiology, May 2007, p. 1640-1643, Vol. 45, No. 5
0095-1137/07/$08.00+0     doi:10.1128/JCM.00143-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»